{"id":"NCT01010971","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older","officialTitle":"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol (160 μg Once Daily and 80 μg Once Daily) for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2009-11-10","resultsPosted":"2012-06-08","lastUpdate":"2012-06-13"},"enrollment":671,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Ciclesonide HFA 160 μg","otherNames":[]},{"type":"DRUG","name":"Ciclesonide HFA 80 μg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ciclesonide HFA Nasal Aerosol 160 μg","type":"EXPERIMENTAL"},{"label":"Ciclesonide HFA Nasal Aerosol 80 μg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This clinical research study will evaluate the safety and effectiveness of two doses of an investigational medication (ciclesonide nasal aerosol) for the treatment of subjects with of seasonal allergic rhinitis (SAR). The study will consist of a Screening Period to confirm study eligibility, followed by a Single-Blind Placebo Run-in period to acclimate subjects to the proper use of the study medication and to assess the subject's severity of SAR symptoms, followed by a 2-week double-blind treatment period to assess the safety and effectiveness of the study medication when given to eligible subjects.","primaryOutcome":{"measure":"Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over the Two-week Treatment Period.","timeFrame":"Week 0-2","effectByArm":[{"arm":"Ciclesonide HFA Nasal Aerosol 160 μg","deltaMin":-1.74,"sd":0.15},{"arm":"Ciclesonide HFA Nasal Aerosol 80 μg","deltaMin":-1.75,"sd":0.15},{"arm":"Placebo","deltaMin":-0.72,"sd":0.16}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":20},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":["22370531"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":225},"commonTop":["Epistaxis"]}}